Results 61 to 70 of about 27,271 (263)
This study investigates how ischemia‐free liver transplantation (IFLT) shapes both local and systemic immune responses compared with conventional liver transplantation (CLT). Our findings demonstrate that IFLT confers significant immunological protection by attenuating the STAT3‐HIF‐1α axis and enhancing the Heme‐HMOX1 pathway, two regulatory networks ...
Tao Luo +40 more
wiley +1 more source
Multiple non-redundant immunosuppressive pathways co-exist in the tumor microenvironment and their co-targeting can increase clinical responses. Indeed, concurrent blockade of CTLA-4 and PD-1 in patients with advanced melanoma increased clinical ...
Heidi Harjunpää +14 more
doaj +1 more source
Advanced ovarian cancer (OC) patients have a poor 5-year survival of only 28%, emphasizing the medical need for improved therapies. Adjuvant immunotherapy could be an attractive approach since OC is an immunogenic disease and the presence of tumor ...
Ralph Ja Maas +13 more
doaj +1 more source
A novel scoring system for TIGIT expression in classic Hodgkin lymphoma
Clinical use of immune-checkpoints inhibitors (anti PD-1/PD-L1) resulted very effective for the treatment of relapsed/refractory classic Hodgkin Lymphoma (CHL).
Ombretta Annibali +7 more
doaj +1 more source
Natural killer cell response to chemotherapy-stressed cancer cells: Role in tumor immunosurveillance. [PDF]
Natural killer (NK) cells are innate cytotoxic lymphoid cells that actively prevent neoplastic development, growth, and metastatic dissemination in a process called cancer immunosurveillance.
Borrelli, Cristiana +5 more
core +1 more source
Single‐cell transcriptomic and functional analyses identify SEMA3C as a key regulator of tumor progression and tumor microenvironment remodeling in penile squamous cell carcinoma. SEMA3C promotes epithelial–mesenchymal transition, tumor growth, and invasion while shaping an immunosuppressive microenvironment, highlighting its potential as a prognostic ...
Xiheng Hu +21 more
wiley +1 more source
Immune checkpoints in circulating and tumor-Infiltrating CD4 + T Cell Subsets in Colorectal cancer patients [PDF]
Blockade of inhibitory immune checkpoints (ICs) is a promising therapeutic approach; however, it has shown limited success in some cancers including colorectal cancer (CRC). The tumor microenvironment (TME) is largely responsible for response to therapy,
Abu Nada, M +5 more
core +2 more sources
PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao +16 more
wiley +1 more source
Gastric cancer (GC) development and progression is significantly associated with tumour immune escape. T cell immunoreceptor with Ig and ITIM domains (TIGIT) inhibits T-cell responses and is associated with human cancers and T cell exhaustion phenotypes,
Weiwei Tang +9 more
doaj +1 more source
Cardiotoxicity of immune checkpoint inhibitors [PDF]
Cardiac toxicity after conventional antineoplastic drugs (eg, anthracyclines) has historically been a relevant issue. In addition, targeted therapies and biological molecules can also induce cardiotoxicity.
Allison +140 more
core +1 more source

